J93 — HCPCS Level II Codes
- J9301 Injection, obinutuzumab, 10 mg billable
- J9302 Injection, ofatumumab, 10 mg billable
- J9303 Injection, panitumumab, 10 mg billable
- J9304 Injection, pemetrexed (pemfexy), 10 mg billable
- J9305 Injection, pemetrexed, not otherwise specified, 10 mg billable
- J9306 Injection, pertuzumab, 1 mg billable
- J9307 Injection, pralatrexate, 1 mg billable
- J9308 Injection, ramucirumab, 5 mg billable
- J9309 Injection, polatuzumab vedotin-piiq, 1 mg billable
- J9311 Injection, rituximab 10 mg and hyaluronidase billable
- J9312 Injection, rituximab, 10 mg billable
- J9313 Injection, moxetumomab pasudotox-tdfk, 0.01 mg billable
- J9314 Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg billable
- J9316 Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg billable
- J9317 Injection, sacituzumab govitecan-hziy, 2.5 mg billable
- J9318 Injection, romidepsin, non-lyophilized, 0.1 mg billable
- J9319 Injection, romidepsin, lyophilized, 0.1 mg billable
- J9320 Injection, streptozocin, 1 gram billable
- J9321 Injection, epcoritamab-bysp, 0.16 mg billable
- J9322 Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mg billable
- J9323 Injection, pemetrexed ditromethamine, 10 mg billable
- J9324 Injection, pemetrexed (pemrydi rtu), 10 mg billable
- J9325 Injection, talimogene laherparepvec, per 1 million plaque forming units billable
- J9326 Injection, telisotuzumab vedotin-tllv, 1 mg billable
- J9328 Injection, temozolomide, 1 mg billable
- J9329 Injection, tislelizumab-jsgr, 1mg billable
- J9330 Injection, temsirolimus, 1 mg billable
- J9331 Injection, sirolimus protein-bound particles, 1 mg billable
- J9332 Injection, efgartigimod alfa-fcab, 2mg billable
- J9333 Injection, rozanolixizumab-noli, 1 mg billable
- J9334 Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc billable
- J9341 Injection, thiotepa (tepylute), 1 mg billable
- J9342 Injection, thiotepa, not otherwise specified, 1 mg billable
- J9345 Injection, retifanlimab-dlwr, 1 mg billable
- J9347 Injection, tremelimumab-actl, 1 mg billable
- J9348 Injection, naxitamab-gqgk, 1 mg billable
- J9349 Injection, tafasitamab-cxix, 2 mg billable
- J9350 Injection, mosunetuzumab-axgb, 1 mg billable
- J9351 Injection, topotecan, 0.1 mg billable
- J9352 Injection, trabectedin, 0.1 mg billable
- J9353 Injection, margetuximab-cmkb, 5 mg billable
- J9354 Injection, ado-trastuzumab emtansine, 1 mg billable
- J9355 Injection, trastuzumab, excludes biosimilar, 10 mg billable
- J9356 Injection, trastuzumab, 10 mg and hyaluronidase-oysk billable
- J9357 Injection, valrubicin, intravesical, 200 mg billable
- J9358 Injection, fam-trastuzumab deruxtecan-nxki, 1 mg billable
- J9359 Injection, loncastuximab tesirine-lpyl, 0.075 mg billable
- J9360 Injection, vinblastine sulfate, 1 mg billable
- J9361 Injection, efbemalenograstim alfa-vuxw, 0.5 mg billable
- J9370 Vincristine sulfate, 1 mg billable
- J9376 Injection, pozelimab-bbfg, 1 mg billable
- J9380 Injection, teclistamab-cqyv, 0.5 mg billable
- J9381 Injection, teplizumab-mzwv, 5 mcg billable
- J9382 Injection, zenocutuzumab-zbco, 1 mg billable
- J9390 Injection, vinorelbine tartrate, 10 mg billable
- J9393 Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg billable
- J9394 Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg billable
- J9395 Injection, fulvestrant, 25 mg billable